Next Article in Journal
BL-038, a Benzofuran Derivative, Induces Cell Apoptosis in Human Chondrosarcoma Cells through Reactive Oxygen Species/Mitochondrial Dysfunction and the Caspases Dependent Pathway
Next Article in Special Issue
Waste Soybean Oil and Corn Steep Liquor as Economic Substrates for Bioemulsifier and Biodiesel Production by Candida lipolytica UCP 0998
Previous Article in Journal
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
Previous Article in Special Issue
Protection of Historical Wood against Microbial Degradation—Selection and Application of Microbiocides
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(9), 1490; doi:10.3390/ijms17091490

The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence

1
Division of Cardiology, Santa Corona Hospital, Via XXV Aprile, 38, Pietra Ligure 17027, Italy
2
Division of Cardiology, San Paolo Hospital, Savona 17100, Italy
3
Department of Cardiology, Bern University Hospital, University of Bern, Bern 3010, Switzerland
4
Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania 95124, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Carl J. Schaschke and Jean-Luc Audic
Received: 27 July 2016 / Revised: 27 August 2016 / Accepted: 31 August 2016 / Published: 6 September 2016
(This article belongs to the Special Issue Biodegradable Materials 2017)
View Full-Text   |   Download PDF [1341 KB, uploaded 6 September 2016]   |  

Abstract

The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer, sirolimus-eluting coronary stent. The high elasticity of the biodegradable-polymer (PDLLA-PCL) and the abluminal gradient coating technology are additional novel features of this coronary device. The Ultimaster DES has undergone extensive clinical evaluation in two studies: The CENTURY I and II trials. Results from these two landmark studies suggested an excellent efficacy and safety profile of the Ultimaster DES across several lesion and patient subsets, with similar clinical outcomes to contemporary, new-generation DES. The aim of this review is to summarize the rationale behind this novel DES technology and to provide an update of available evidence about the clinical performance of the Ultimaster DES. View Full-Text
Keywords: Ultimaster stent; biodegradable polymer drug eluting stent; new-generation DES; sirolimus-eluting stent; coronary stent Ultimaster stent; biodegradable polymer drug eluting stent; new-generation DES; sirolimus-eluting stent; coronary stent
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chisari, A.; Pistritto, A.M.; Piccolo, R.; La Manna, A.; Danzi, G.B. The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence. Int. J. Mol. Sci. 2016, 17, 1490.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top